報價延遲最少15分鐘:2026/07/04 14:58 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.83 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.84/1.22
|
|
企業價值
44.29B
|
| 資產負債 |
|
每股賬面淨值
5.53
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
15.12B
|
|
每股收益
8.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, includingTylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026. |
